The president has signed an executive order stating that the US will institute a “most-favored-nation” policy, whereby the US will pay the same price for a drug as the nation that pays the lowest ...

New research suggests that outpatients with cancer are more likely than other outpatients to have antimicrobial-resistant bacterial pathogens.

The researchers also observed significant increases in mortality for at least 1 age group for the following cancers: testicular cancer, uterine cancer, female breast cancer, bone and joint cancer, ...

Pharmaceutical tariffs could increase drug prices and drug shortages, negatively impacting the health care system, experts warn.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

Despite a congressional mandate to expand care for veterans, internal Veterans Affairs messages obtained by ProPublica paint a stark portrait of how chaotic cost cutting has already imperiled tests of ...

(HealthDay News) — The new commissioner of the US Food and Drug Administration (FDA), Dr Marty Makary, has shared details about his first weeks on the job, his vision for the future, and why he ...

The FDA's decision to grant INX-315 fast track designation was based on preclinical data and interim data from the ongoing phase 1/2 INX-315-01 trial. The US Food and Drug Administration (FDA) has ...

The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.

Adding an immune checkpoint inhibitor to neoadjuvant chemotherapy can improve pathologic complete response rates and may improve survival in patients with muscle-invasive bladder cancer, research ...

The Trump administration has terminated National Institutes of Health (NIH) grants totaling more than $1.8 billion, and the National Cancer Institute (NCI) is among the top 5 institutes with the most ...

Experts say the Trump administration's cancellation of more than $800 million in research focused on LGBTQ patients could harm public health.